Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, Open-label, Dose Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of RLX030 in Addition to Standard of Care in Pediatric Patients From Birth to less than 18 Years of Age, Hospitalized With Acute Heart Failure

Next Previous
X
Search
Trial Profile

Multicenter, Open-label, Dose Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of RLX030 in Addition to Standard of Care in Pediatric Patients From Birth to less than 18 Years of Age, Hospitalized With Acute Heart Failure

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Jun 2019

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Serelaxin (Primary)
  • Indications Acute heart failure
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms RELAX-PEDS-PK
  • Sponsors Novartis Pharmaceuticals Corporation

    • Most Recent Events

    • 22 May 2017 Status changed from recruiting to discontinued.
    • 28 Feb 2017 Planned End Date changed from 1 Dec 2017 to 13 Apr 2018.
    • 28 Feb 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Apr 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top